• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.

作者信息

Tse C S, Loftus E V, Raffals L E, Gossard A A, Lightner A L

机构信息

Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.

DOI:10.1111/apt.14907
PMID:30156321
Abstract
摘要

相似文献

1
Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.
2
Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise?
Aliment Pharmacol Ther. 2018 Sep;48(5):576-577. doi: 10.1111/apt.14858.
3
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.维得利珠单抗、阿达木单抗和英夫利昔单抗对原发性硬化性胆管炎和炎症性肠病个体胆道炎症的影响。
Aliment Pharmacol Ther. 2018 Jul;48(2):190-195. doi: 10.1111/apt.14829. Epub 2018 May 28.
4
Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.生物疗法在炎症性肠病肠外表现管理中的应用
Inflamm Bowel Dis. 2007 Nov;13(11):1424-9. doi: 10.1002/ibd.20196.
5
Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.信函：维多珠单抗用于自身免疫性肝病相关的炎症性肠病——作者回复
Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.
6
[Place of biologic therapy in the treatment of inflammatory bowel diseases and assessment of its efficacy].[生物疗法在炎症性肠病治疗中的地位及其疗效评估]
Acta Med Croatica. 2013 Apr;67(2):145-55.
7
Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.
Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570.
8
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis.在维多珠单抗治疗炎症性肠病和原发性硬化性胆管炎患者中，并非所有闪光的都是金子。
Clin Gastroenterol Hepatol. 2020 Jan;18(1):51-53. doi: 10.1016/j.cgh.2019.07.020. Epub 2019 Jul 16.
9
[Biological therapy in women with inflammatory bowel disease during pregnancy].[妊娠期炎症性肠病女性的生物治疗]
Vnitr Lek. 2014 Jul-Aug;60(7-8):630-4.
10
Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
Aliment Pharmacol Ther. 2017 Mar;45(6):856-857. doi: 10.1111/apt.13968.